- Déficit Androgénique Lié à l’Âge
- Published:
Contribution de la testostérone biodisponible aux explorations hormonales pour le diagnostic de l’andropause
Bioavailable testosterone in the hormonal screening for the diagnosis of «andropause»
Andrologie volume 13, pages 105–109 (2003)
Resume
La mesure de la testostérone biodisponible (TB) est considérée comme le critère analytique essentiel au diagnostic de l’hypogonadisme masculin mais les valeurs de référence diffèrent sensiblement d’un auteur à l’autre et il n’existe pas encore de consensus sur celles qui définissent une hypoandrogénie liée à l’âge. Nous avons établi nos propres valeurs seuils définies comme les valeurs minimales mesurées au sein d’une population d’hommes de 40–49 ans cliniquement normogonadiques, soit 8 nmol/l pour la testostéronémie totale et 3,5 nmol/l pour la TB. En appliquant ces critères à un groupe de 87 hommes présentant des symptômes cliniques de déficit androgénique, ceux pouvant être classés comme biologiquement hypoandrogéniques et candidats à une androgénothérapie n’étaient que 14% en fonction de la testostéronémie totale, mais 60% en fonction de la TB. La corrélation inverse entre TB et SHBG pour un taux de testostérone totale défini a été retrouvée quel que soit le niveau de la testostéronémie. La mesure de la SHBG constitue une aide précieuse pour le diagnostic d’hypoandrogénie dans une population d’hommes âgés mais ne peut se substituer à une mesure directe de la TB pour un diagnostic individuel.
Abstract
The measurement of bioavailable testosterone (BT) is considered to be an essential analytical criterion for the diagnosis of male hypogonadism, but the reported normal values differ from one study to another and no consensus has been reached concerning the cut-off values for the diagnosis of androgen deficiency in aging males. Using the lower values measured in a group of clinically normogonadic men between the ages of 40 and 49 years, we have established our own cut-off values: 8 nmol/L for total testosterone and 3.5 nmol/L for BT. By applying these criteria to a group of 87 men with clinical symptoms of androgen deficiency, androgen deficiency was confirmed by laboratory assays in only 14% of these men based on total testosterone, but in 60% of men based on BT. The inverse correlation between BT and SHBG was confirmed regardless of the total testosterone level. SHBG assay is very useful for the diagnosis of androgen deficiency in a population of older males, but cannot replace direct measurement of BT for an accurate individual diagnosis.
Références
BHASIN S., BUCKWALTER J.G.: Testosterone supplementation in older men: a rational idea whose time has not yet come. J. Androl., 2001, 22: 718–731.
DORGAN J.F., FEARS T.R., McMAHON R.P., et al.: Measurement of steroid sex hormones in serum: a comparison of radioimmunoassay and mass spectrometry. Steroids, 2002, 67: 151–158.
FELDMAN H.A., LONGCOPE C., DERBY C.A., et al.: Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J. Clin. Endocrinol. Metab., 2002, 87: 589–598.
FERRINI R.L., BARRETT-CONNOR E.: Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am. J. Epidemiol., 1998, 147: 750–754.
GOULD D.C., PETTY R., JACOBS H.S.: The male menopause does-it exist? Br. Med. J., 2000, 320: 858–861.
GRAY A., FELDMAN H.A., MCKINLAY J.B., LONGCOPE C.: Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J. Clin. Endocrinol. Metab., 1991, 73: 1016–1025.
HAREN M.T., MORLEY J.E., CHAPMAN I.M., et al.: Defining relative androgen deficiency in aging men: how should testosterone be measured and what are the relationships between androgen levels and physical, sexual and emotional health? Climacteric, 2002, 5: 15–25.
HARMAN S.M., METTER E.J., TOBIN J.D., et al.: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J. Clin. Endocrinol. Metab., 2001, 86: 724–731.
HAYES F.J.: Testosterone-Fountain of youth or drug of abuse? J. Clin. Endocrinol. Metab., 2000, 85: 3020–3023.
KRIEG M., NASS R., TUNN S.: Effect of aging on endogenous level of 5a-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J. Clin. Endocrinol. Metab., 1993, 77: 375–381.
KRIEG M., WEISSER H., TUNN S.: Potential activities of androgen metabolizing enzymes in human prostate. J. Steroid. Biochem. Mol. Biol., 1995, 53: 395–400.
LABRIE F., BELANGER A., CUSAN L., et al.: Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab., 1997, 82: 2396–2402.
MATSUMOTO A.M.: Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J. Gerontol. Med. Sci., 2002, 57A: M76-M99.
SHIBATAY Y., ITO K., SUZUKI K., et al.: Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate, 2000, 42: 45–55.
TREMBLAY R.R.: Practical consequences of the validation of a mathematical model in assessment of partial androgen deficiency in the aging male using bioavailable testosterone. Aging Male, 2001, 4: 23–29.
VELDHUIS J.D., ZWART A., MULLIGAN T., IRANMANESH A.: Muting of androgen negative feedback unveils impoverished gonadotropin-releasing hormone/luteinizing hormone secretory reactivity in healthy older men. J. Clin. Endocrinol. Metab., 2001, 86: 529–535.
VERMEULEN A., VERDONCK L., KAUFMAN J.M.: A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab., 1999, 84: 3666–3672.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brisson, G., Duval, L.P. & de Lignières, B. Contribution de la testostérone biodisponible aux explorations hormonales pour le diagnostic de l’andropause. Androl. 13, 105–109 (2003). https://doi.org/10.1007/BF03034422
Issue Date:
DOI: https://doi.org/10.1007/BF03034422
Mots Clés
- testostéronémie
- testostérone biodisponible
- SHBG
- hypoandrogénie liée à l’âge
- andropause
Key-Words
- testosterone
- bioavailable testosterone
- SHBG
- hypogonadism
- andropause